Lumos Pharma to Host Key Opinion Leader Event on LUM-201 for the Treatment of Pediatric Growth Hormone Deficiency Nasdaq:LUMO

AUSTIN, Texas, April 14, 2021 (GLOBE NEWSWIRE) – Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-stage biopharmaceutical company focused on drugs for rare diseases, today announced that it will host a key opinion leader (KOL) webinar on LUM-201 on Tuesday, April 27, 2021 at 10:30 a.m.ET. LUM-201 is the company’s orally administered therapeutic candidate for the treatment of pediatric growth hormone deficiency (PGHD).

The event will feature presentations from KOLs in the field of pediatric endocrinology, Bradley S. Miller, MD, Ph.D., University of Minnesota, and Fernando Cassorla, MD, University of Chile, who discussed currently available treatments and medical needs in PGHD. Drs. Miller and Cassorla will be available to answer questions after their formal presentations.

The Lumos Pharma management team will also provide a company update and discuss the OraGrowtH clinical program to evaluate LUM-201 in PGHD. Growth hormone (GH) deficiency results from insufficient secretion of growth hormone from the pituitary gland, resulting in low GH in the body, insufficient production of downstream signaling molecules necessary for growth, and the subsequent lack of growth. LUM-201, also known as ibutamoren, is an orally administered experimental small molecule that promotes secretion of GH from the pituitary gland and provides an opportunity for appropriately selected patients to avoid the daily or weekly injections associated with current or future therapies. LUM-201 has been observed to increase the amplitude of endogenous pulsatile GH secretion, mimicking the natural pattern of GH secretion.

Click on the link to register for this event here

KOL Biographies

Dr. Bradley S. Miller is currently a professor, department of pediatrics and faculty member, department director, department of pediatric endocrinology, at the University of Minnesota Medical School. He is a practicing pediatric endocrinologist and published researcher with an interest in the role of the GH / IGF system on normal and abnormal growth in children. His other areas of interest include the growth and development of children after adversity such as cancer and cancer therapy, fetal alcohol exposure and international adoption. Dr. Miller received his MD and PhD from the Medical University of South Carolina, Charleston. He completed his residency and fellowship in pediatrics and pediatric endocrinology, respectively, at the Mayo Clinic. Dr. Miller has received numerous awards and recognition throughout his medical education and career and is actively involved with the MAGIC Foundation for Children’s Growth, the world leader in endocrine health, advocacy, education and support.

Dr. Fernando Cassorla is currently Chief of Pediatric Endocrinology at the Institute of Maternal and Child Research at the University of Chile, a position he has held since 1993. Previously, Dr. Cassorla Senior Investigator in the Developmental Endocrinology Branch of the National Institute of Child Health and Human Development, rising to the position of clinical director of this institute in 1990. He has numerous chapters in the field of pediatric endocrinology, author or co-author of more than 200 original articles in peer-reviewed journals, and has presented more than 300 abstracts at scientific meetings. Dr. Cassorla received his MD from the University of Chile. He is Board Certified in both pediatric and pediatric endocrinology after completing his pediatric residency at Albany Medical Center in New York and his fellowship in pediatric endocrinology at the Children’s Hospital of Philadelphia. Dr. Cassorla has received several international awards for his work and was elected to the Chilean Academy of Medicine for a lifetime position in 2003.

About Lumos Pharma
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases. Lumos Pharma was founded and led by a management team with years of experience in rare disease drug development and received early funding from leading healthcare investors including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone-stimulating small molecule, currently being evaluated in a phase 2b clinical trial, the OraGrowtH210 trial, for the treatment of pediatric growth hormone deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients undergo over many years of treatment. The LUM-201 has been granted orphan drug designation in both the US and the EU. For more information, please visit https://lumos-pharma.com/.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements from Lumos Pharma, Inc. (the “Company”) that involve significant risks and uncertainties. All such statements in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “forecast”, “projected”, “guidance”, “forthcoming”, “will”, “should,” “plan” , “intend”, “anticipate”, “approach”, “expect”, “potential”, “imminent” or the negative of these terms and conditions or other similar expressions are intended to identify forward-looking statements, although not all contain forward-looking statements these identifying words. These forward-looking statements include, among other things, plans to conduct clinical trials and statements other than statements of historical fact. Actual results or events may differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the company does because of a number of important factors, including its securities pandemics or other widespread health concerns such as the ongoing COVID-19 pandemic, the outcome of our future interactions with regulatory authorities, the outcome of our Phase 2b OraGrowtH210 trial for LUM-201, our ability to predict future use of cash and reserves necessary for contingent future liabilities and business activities, the availability of adequate resources for our surgeries and to conduct or continue planned clinical development programs, the ability to obtain the necessary patient enrollment for our product candidate in a timely manner, the ability to maintain our product candidate, the risks associated with the development process, obtain regulatory approval for and commercialize drug candidates such as LUM-201 that are safe and effective for use as human therapeutics, the timing and ability of Lumos to necessary bi raising equity and other risks that could cause actual results to differ materially from those expressed in or implied by such forward-looking statements as discussed in Factors’ and elsewhere in the company’s annual report on Form 10-K for the year ended December 31, 2020 and other reports filed with the SEC. The forward-looking statements in this press release represent the company’s views as of the date of this press release. The company expects that subsequent events and developments will cause their views to change. However, while it may choose to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so. Therefore, you should not rely on these forward-looking statements to represent the company’s views as of any date after the date of this press release.

Investor & Media Contact:
Lisa Miller
Investor Relations of Lumos Pharma
512-792-5454
ir@lumos-pharma.com

Corey Davis, PhD
LifeSci Advisors
cdavis@lifesciadvisors.com

Comments are closed.